Abstract
Albuminuria has been shown to be associated with cardiovascular and noncardiovascular mortality in the general population, with malignant neoplasms accounting for a large proportion of the noncardiovascular deaths. Although a possible association between proteinuria and cancer has been discussed for more than 40 years, it is still unclear whether albuminuria is associated with cancer incidence. Jørgensen et al. monitored 5,425 study participants who did not have diabetes, macroalbuminuria or previous cancer at baseline, for a mean of 9.1 years. This population-based longitudinal study showed a relationship between increasing albuminuria and risk of cancer, although the finding is hypothesis generating rather than hypothesis testing. This Practice Point commentary discusses the findings and limitations of this observational study and highlights the issues related to the relationship between albuminuria and cancer. In addition, possible underlying mechanisms and the need for further investigation are discussed.
This is a preview of subscription content, log in via an institution to check access.
References
Norris SH (1993) Paraneoplastic glomerulopathies. Semin Nephrol 13: 258–272
Hillege HL et al. (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777–1782
Jørgensen L et al. (2008) Association of albuminuria and cancer incidence. J Am Soc Nephrol 19: 992–998
Russo A et al. (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44: 293–297
Lever AF et al. (1998) Do inhibitors of angiontensin-I-converting enzyme protect against risk of cancer. Lancet 352: 179–184
Leenen FH et al. (2006) Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48: 374–384
Lindholm LH et al. (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358: 539–544
Baigent C et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Furumatsu, Y., Imai, E. Albuminuria is associated with the incidence of some cancers in nondiabetic individuals. Nat Rev Nephrol 4, 588–589 (2008). https://doi.org/10.1038/ncpneph0945
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0945
- Springer Nature Limited